These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 27272204)

  • 21. [Early daunorubicin cardiotoxicity and fatal outcome in a child with acute myeloblastic leukemia (M2)].
    Rizzari C; Santamaria M; Galli MA; Jankovic M; Uderzo C
    Pediatr Med Chir; 1987; 9(6):749-50. PubMed ID: 3481847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma.
    Gill PS; Wernz J; Scadden DT; Cohen P; Mukwaya GM; von Roenn JH; Jacobs M; Kempin S; Silverberg I; Gonzales G; Rarick MU; Myers AM; Shepherd F; Sawka C; Pike MC; Ross ME
    J Clin Oncol; 1996 Aug; 14(8):2353-64. PubMed ID: 8708728
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Cardiotoxicity of daunorubicin and aclacinomycin A in patients with acute leukemia].
    Haruyama H; Shimazaki C; Nakanishi S; Hamami T; Nisio A; Isemura T; Katsume H; Nakagawa M; Ijichi H
    Gan To Kagaku Ryoho; 1982 Mar; 9(3):516-21. PubMed ID: 6964037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Administration schedule of daunorubicin for elderly patients with acute myelogenous leukemia: a single-institute experience.
    Dobashi N; Usui N; Yano S; Yahagi Y; Takei Y; Sugiyama K; Takahara S; Ogasawara Y; Yamaguchi Y; Saito T; Yokoyama H; Aiba K
    Jpn J Clin Oncol; 2011 Jun; 41(6):820-4. PubMed ID: 21415001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The cardiotoxicity of anticancer agents.
    Von Hoff DD; Rozencweig M; Piccart M
    Semin Oncol; 1982 Mar; 9(1):23-33. PubMed ID: 7071608
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Daunorubicin cardiotoxicity in childhood cancer.
    Samuel L; Cummings J; Shaw P
    Lancet; 1998 Oct; 352(9134):1150. PubMed ID: 9798620
    [No Abstract]   [Full Text] [Related]  

  • 27. [Echocardiographic evaluation of cardiotoxicity induced by anthracycline therapy].
    Okada Y; Horikawa K; Sano M
    Gan To Kagaku Ryoho; 1997 Mar; 24(5):585-9. PubMed ID: 9087292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L; Bramwell V; Moran LA
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cardiotoxicity of adriamycin and daunomycin in children.
    Gilladoga AC; Manuel C; Tan CT; Wollner N; Sternberg SS; Murphy ML
    Cancer; 1976 Feb; 37(2 Suppl):1070-8. PubMed ID: 1253124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Chemotherapy-induced cardiotoxicity: Incidence, diagnosis and prevention].
    Nelson-Veniard M; Thambo JB
    Bull Cancer; 2015; 102(7-8):622-6. PubMed ID: 25935231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiotoxicity from anthracycline and cardioprotection in paediatric cancer patients.
    Bassareo PP; Monte I; Romano C; Deidda M; Piras A; Cugusi L; Coppola C; Galletta F; Mercuro G
    J Cardiovasc Med (Hagerstown); 2016 May; 17 Suppl 1 Special issue on Cardiotoxicity from Antiblastic Drugs and Cardioprotection():e55-e63. PubMed ID: 27755243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Trial of chemotherapy with a new antimitotic derivative].
    Chauvergne J
    Nouv Presse Med; 1973 Mar; 2(9):581. PubMed ID: 4703337
    [No Abstract]   [Full Text] [Related]  

  • 33. Safety and potential effectiveness of daunorubicin-containing liposomes in patients with advanced recurrent malignant CNS tumors.
    Boiardi A; Pozzi A; Salmaggi A; Eoli M; Zucchetti M; Silvani A
    Cancer Chemother Pharmacol; 1999; 43(2):178-9. PubMed ID: 9923826
    [No Abstract]   [Full Text] [Related]  

  • 34. Stem cells: The cancer's gone, but did chemotherapy damage your heart?
    Bellin M; Mummery CL
    Nat Rev Cardiol; 2016 Jul; 13(7):383-4. PubMed ID: 27226155
    [No Abstract]   [Full Text] [Related]  

  • 35. Cardiac effects of anthracyclines used in the treatment of childhood acute lymphoblastic leukemia: a 10-year experience.
    Sallan SE; Clavell LA
    Semin Oncol; 1984 Dec; 11(4 Suppl 3):19-21. PubMed ID: 6594762
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical spectrum of anthracycline antibiotic cardiotoxicity.
    Bristow MR; Billingham ME; Mason JW; Daniels JR
    Cancer Treat Rep; 1978 Jun; 62(6):873-9. PubMed ID: 667861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Daunorubicin 90 mg/m
    Portugal R; Lyrio R; Loureiro M; Urago K; Bard J; Borchardt A; Garnica M; Nucci M
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):527-531. PubMed ID: 28842139
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subclinical anthracycline-induced cardiotoxicity in long-term follow-up of asymptomatic childhood cancer survivors: Assessment by speckle tracking echocardiography.
    Çetin S; Babaoğlu K; Başar EZ; Deveci M; Çorapçıoğlu F
    Echocardiography; 2018 Feb; 35(2):234-240. PubMed ID: 29106752
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk factors for development of daunorubicin cardiotoxicity.
    Von Hoff DD; Layard M
    Cancer Treat Rep; 1981; 65 Suppl 4():19-23. PubMed ID: 7049377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination chemotherapy for advanced sarcomas of bone and mesothelioma utilizing rubidazone and DTIC: a Southwest Oncology Group Study.
    Zidar BL; Benjamin RS; Frank J; Lane M; Baker LH
    Am J Clin Oncol; 1983 Feb; 6(1):71-4. PubMed ID: 6837508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.